target-validation

name	target-validation
description	Comprehensive target validation assessing druggability, disease association strength, tractability, and competitive landscape. Use for go/no-go decisions on target selection. Keywords: target validation, druggability, tractability, disease association, genetic validation
category	Target Analysis
tags	["target","validation","druggability","tractability","genetics"]
version	1.0.0
author	Drug Discovery Team
dependencies	["opentargets","gwas-catalog","clinvar","uniprot"]

Target Validation Skill

Comprehensive target validation for drug discovery decision-making.

Quick Start

/target-validate EGFR --full
/validate "KRAS G12C" --association oncology
/tractability --target "BCR-ABL" --include genetic,chemical,clinical

Validation Framework

The 4-Pillar Framework

1. Genetic Validation
   ├── GWAS associations
   ├── Mendelian randomization
   ├── CRISPR screens
   └── Animal models

2. Chemical Validation
   ├── Known binders
   ├── Tool compounds
   ├── Co-crystal structures
   └── SAR coverage

3. Clinical Validation
   ├── Approved drugs
   ├── Pipeline drugs
   ├── Genetic therapies
   └── Biomarker linkage

4. Competitive Landscape
   ├── Active companies
   ├── Patent density
   ├── Differentiation potential
   └── Market maturity

Output Structure

# Target Validation: EGFR

## Validation Summary

| Pillar | Score | Status |
|--------|-------|--------|
| Genetic | 5/5 | ✓ Strong |
| Chemical | 5/5 | ✓ Strong |
| Clinical | 5/5 | ✓ Strong |
| Competition | 2/5 | ⚠ Crowded |

**Overall Validation**: Strong (17/20)

## Genetic Validation

### Human Genetics

| Evidence | Score | Details |
|----------|-------|---------|
| GWAS | 5/5 | 5 genome-wide significant associations |
| Mendelian | 5/5 | Activating mutations cause lung cancer |
| Somatic | 5/5 | Mutations in 15% NSCLC |
| eQTL | 4/5 | Strong expression QTLs |
| PheWAS | 3/5 | Cancer-associated phenotypes |

**Key Studies**:
- Zhang et al. (2020): OR = 2.5, p = 2×10⁻¹²
- Mendelian randomization supports causality

### Animal Models

| Model | Evidence | Phenotype |
|-------|----------|----------|
| Knockout mouse | 5/5 | Lung development defects |
| Transgenic (mutant) | 5/5 | Tumor formation |
| Zebrafish | 3/5 | Developmental phenotype |

## Chemical Validation

### Known Binders

| Compound | Type | Potency | Status |
|----------|------|---------|--------|
| Erlotinib | Small molecule | 2 nM | Approved |
| Osimertinib | Small molecule | 1 nM | Approved |
| Cetuximab | Biologic | 0.1 nM | Approved |
| Amivantamab | Biologic | 0.5 nM | Phase 3 |

### Structural Coverage

| Metric | Value |
|--------|-------|
| PDB entries | 127 |
| Co-crystals | 89 |
| Active conformations | 45 |
| Inactive conformations | 12 |

**Conclusion**: Excellent structural coverage for SBDD

## Clinical Validation

### Approved Drugs

| Drug | Indication | Year | Sales |
|------|-----------|------|-------|
| Erlotinib | NSCLC | 2004 | $1.5B |
| Gefitinib | NSCLC | 2002 | $0.8B |
| Osimertinib | NSCLC | 2015 | $5.2B |
| Afatinib | NSCLC | 2013 | $0.3B |

### Pipeline Drugs

| Drug | Company | Phase | Indication |
|------|---------|-------|------------|
| Lazertinib | J&J | 3 | NSCLC |
| Nazartinib | Novartis | 2 | NSCLC |

**Clinical Confidence**: Proven mechanism with multiple approvals

## Competitive Landscape

### Active Companies (2024)

| Company | Phase | Assets |
|---------|-------|--------|
| AstraZeneca | 3 | 3rd-gen TKI |
| Johnson & Johnson | 3 | 4th-gen TKI |
| Roche | 2 | Biologics |
| Merck | 1 | ADC |
| BeiGene | 2 | TKI |



| Metric | Value |
|--------|-------|
| Active patents | 245 |
| Key patents expiring | 2030-2035 |
| White space | 4th-gen, combinations |

: High competition but proven market





| Metric | Score | Details |
|--------|-------|---------|
| Class | A | Kinase, well-characterized |
| Binding site | A | ATP pocket, drug-like |
| Location | A | Cell surface (TKI) |
| Assayability | A | Biochemical, cellular |
| Selectivity | B | Kinome-wide selectivity needed |

: Highly tractable (class A kinase)



| Risk | Level | Mitigation |
|------|-------|-----------|
| Safety | Medium | Cardiac toxicity monitoring |
| Resistance | High | 3rd/4th-gen solutions |
| Competition | High | Differentiate on resistance |
| IP | Medium | Novel chemical series |



: GO - Proceed with EGFR program

:
 Strong genetic validation
 Proven clinical mechanism
 Tractable target
 Large market despite competition

:
 Focus on resistance mutations (C797S)
 Combination approaches
 CNS-penetrant molecules

:
 Review 4th-gen competitive landscape
 Assess CNS penetration opportunity
 Evaluate combination strategies

Validation Scoring

Genetic Evidence (0-5)

Score	Criteria
5	Definitive causal link (Mendelian)
4	Strong GWAS + functional validation
3	GWAS association only
2	Moderate association
1	Weak genetic evidence
0	No genetic evidence

Chemical Evidence (0-5)

Score	Criteria
5	Multiple drug classes, many binders
4	Several binders, good SAR
3	Some binders, limited SAR
2	Few tool compounds
1	Probes only
0	No chemical matter

Clinical Evidence (0-5)

Score	Criteria
5	Multiple approved drugs
4	One approved, others in pipeline
3	Late-stage pipeline
2	Early clinical evidence
1	Preclinical only
0	No clinical evidence

Running Scripts

# Full validation
python scripts/target_validation.py EGFR --full

# Association analysis only
python scripts/target_validation.py KRAS --association oncology

# Tractability assessment
python scripts/tractability.py --target "BCR-ABL" --structure

# Comparison
python scripts/target_validation.py EGFR KRAS ALK --compare

Requirements

pip install requests pandas numpy

# Optional for advanced features
pip install scipy statsmodels

Reference

• reference/validation-methods.md - Validation methodology
• reference/genetics.md - Genetic validation reference
• reference/tractability.md - Tractability assessment

Best Practices

1. Use multiple evidence types: No single source sufficient
2. Weight clinical highest: Approved drugs = strongest validation
3. Consider disease: Oncology targets different from CNS
4. Assess timing: Early targets = higher risk/reward
5. Review competition: Impacts differentiation strategy

Common Pitfalls

Pitfall	Solution
Over-reliance on expression	Functional validation needed
Ignoring genetics	Human genetics predicts clinical success
Late to crowded targets	Early differentiation key
Undervaluing safety	Safety failures expensive
Single-source bias	Triangulate evidence